Comparative Pharmacology
Head-to-head clinical analysis: DOLISHALE versus KADIAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOLISHALE versus KADIAN.
DOLISHALE vs KADIAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DOLISHALE is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, enhancing serotonin neurotransmission.
Mu-opioid receptor agonist; modulates pain perception and emotional response to pain.
Adults: 200 mg orally twice daily or 400 mg orally once daily. Administer with food.
20-100 mg orally every 12 hours; titration based on pain severity and prior opioid exposure.
None Documented
None Documented
Terminal elimination half-life: 12 hours (range 10-14) in adults; prolonged in renal impairment (up to 24 hours with CrCl <30 mL/min)
Terminal elimination half-life of morphine: 2–4 hours; KADIAN extended-release formulation: effective half-life ~12 hours due to prolonged absorption, dosing q12h or q24h
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Renal: primarily as morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G); ~90% of total elimination is renal, with 10% biliary/fecal
Category C
Category C
Opioid Analgesic
Opioid Analgesic